Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT

Inclusion Criteria: * New Diagnosed advanced myelodysplastic syndrome (MDS) for whom an allogeneic hematopoietic stem cell transplant is planned * Recipient of an allogeneic hematopoietic stem cell transplantation * Age \< 65 years * ECOG performance status ≤2 * Written informed consent * No psychological, familial, social, or geographic reason that would compromise clinical follow up Exclusion Criteria: * Relapsed or refractory advanced MDS * Severe pshyciatric or organic disorder, supposed to be independent from advanced MDS, that would contraindicate treatment * Known allergic or hypersensitivity to azacitidine, aclarubicin or cytarabine or to any of the test compounds, materials * Concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place the subject at unacceptable risk * A co-morbid condition which, in the view of the Investigators, renders the subject at high risk from treatment complications